Cardiff Oncology, Inc.
CRDF
$4.00
$0.051.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.57% | -0.65% | -17.65% | -7.22% | 4.05% |
| Total Depreciation and Amortization | -4.95% | -3.81% | 2.94% | -0.97% | -3.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.56% | 4.18% | 8.68% | 37.50% | 9.32% |
| Change in Net Operating Assets | 87.13% | -85.48% | 15.82% | -13.66% | 35.97% |
| Cash from Operations | 1.81% | -13.28% | -19.25% | -8.42% | 10.28% |
| Capital Expenditure | -- | -- | 100.00% | -900.00% | 97.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 147.82% | -167.31% | 197.18% | -65.24% | 228.07% |
| Cash from Investing | 147.82% | -167.31% | 202.31% | -65.81% | 254.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 494.96% | 260.88% | 1,823.36% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 494.96% | 260.88% | 1,823.36% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 408.37% | -282.13% | 328.33% | -146.67% | 255.27% |
